NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.

Speaking at the Morgan Stanley Healthcare Conference, Chief Executive Officer Tony Zook said the company remains focused exclusively on oncology and on serving community providers, where it estimates nearly 80% of patients receive treatment.

NeoGenomics began with diagnostic testing but has expanded its portfolio to include therapy selection and MRD testing, he said.

Zook said investors may underestimate the company’s existing NGS business. Although NGS represents about 10% of NeoGenomics’ test volume, it accounts for roughly one-third of clinical revenue, he said. The company’s NGS portfolio exceeds $250 million in revenue and was growing 26%, according to Zook.

Zook and Chief Operating Officer and President Warren Stone differentiated the company’s approach to community oncology from that of providers focused on academic medical centers. Community physicians often operate under time constraints, see a broad range of cancer types and require practical, guideline-based testing workflows, the executives said.

Stone said NeoGenomics offers nearly 500 tests spanning diagnosis, therapy selection, MRD, solid tumors and hematologic cancers. The breadth of that portfolio can allow providers to standardize their external testing with a single laboratory partner, he said.

NeoGenomics is seeking to reduce administrative and clinical friction through care pathways and simplified ordering. Stone cited the company’s PanTracer Pro offering, launched earlier this year, which enables physicians to provide a patient’s cancer type and stage while NeoGenomics determines the appropriate testing approach based on guidelines and its OncoTree classification system. The resulting report can include potential therapy options and available clinical trials, Stone said. The company may also perform reflex testing or add-on testing where needed.

"It’s not distinct products. It’s really around a workflow solution," Stone said of the PanTracer family, which includes tissue- and liquid-based offerings for solid-tumor therapy selection.

Chief Financial Officer Abhishek Jain said NGS revenue increased 26% during the first half of 2026. Volume growth was in the mid-teens, with the remainder of the increase stemming from revenue-cycle-management, or RCM, initiatives. Jain said larger NGS panels are growing more than 20% as the company sees a shift away from single-gene and targeted panels. That mix shift ...